Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 3218 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
William Stohl¹, Andreas Schwarting², Masato Okada³, Morton Scheinberg⁴, Andrea Doria⁵, Anne Hammer⁶, Christi Kleoudis⁷, Damon Bass⁸, James Groark⁹, Norma Lynn Fox¹⁰, David Roth¹¹ and David Gordon¹¹, ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²ACURA Kliniken, Bad Kreuznach, Germany, ³Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, ⁵Division of Rheumatology, University of Padova, Padova, Italy, ⁶GlaxoSmithKline, Research Triangle Park, NC, ⁷Parexel, Durham, NC, ⁸Immuno-Inflammation, GlaxoSmithKline, King of Prussia, PA, ⁹GlaxoSmithKline, Philadelphia, NC, ¹⁰GlaxoSmithKline, Washington, MD, ¹¹GlaxoSmithKline, Philadelphia, PA
Background/Purpose: To assess the efficacy and safety of belimumab (BEL) administered subcutaneously plus standard SLE care (SoC) in patients with active SLE.Methods: BLISS-SC (BEL112341; NCT01484496)…
Abstract Number: 697 • 2014 ACR/ARHP Annual Meeting
Venous and Arterial Thrombosis in SLE: Differences in Natural History
Katharine Hickman¹, Laurence S. Magder² and Michelle Petri³, ¹University College London, London, United Kingdom, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Thrombosis is increased in SLE due to disease activity and co-morbid factors including antiphospholipid antibodies. We separately investigated the natural history of venous vs.…
Abstract Number: 689 • 2014 ACR/ARHP Annual Meeting
Prednisone, Disease Activity and Hypertension Independently Predict Cataracts in Systemic Lupus Erythematosus (SLE)
Khaled Alderaan¹, Vuk Sekicki², Laurence S. Magder³ and Michelle Petri⁴, ¹King Fahad Specilaist Hospital, Dammam, Saudi Arabia, ²Medicine, Saint Agnes Hospital, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Cataract is the most common ocular damage in SLE. It is the second most frequent item in the SLICC/ACR Damage Index. Apart from cumulative…
Abstract Number: 2675 • 2014 ACR/ARHP Annual Meeting
The Selective Loss of SLAMF4⁺ CD8⁺ T Cells Contributes to the Decreased Cytotoxic Capacity Observed in Systemic Lupus Erythematosus
Katalin Kis-Toth¹, Denis Comte¹, Maria Karampetsou¹, Lakshmi Kannan² and George C. Tsokos¹, ¹Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ²Rheumtology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose Signaling lymphocytic activation molecule family member 4 (SLAMF4) engagement by its ligand SLAMF2 can mediate the cytotoxicity of CD8+ T cells and natural killer…
Abstract Number: 677 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Biological Activity of Intravenously or Subcutaneously Administered Tabalumab in Subjects with Rheumatoid Arthritis or Systemic Lupus Erythematosus
Jennifer Witcher¹, Ryan Hansen¹, Leijun Hu¹, David Radtke¹, James Voelker¹ and Juliet McColm², ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Windlesham, United Kingdom
Background/Purpose : B-cell activating factor (BAFF) promotes B-cell survival and maturation, and increased serum levels are associated with autoimmune disease and disease activity in systemic…
Abstract Number: 2674 • 2014 ACR/ARHP Annual Meeting
The Effect and Mechanisms of Icaritin on Regulating Foxp3/IL17a Expression in CD4⁺ T Cells from SLE
Jieyue Liao¹, Yu Liu², Ming Zhao³, hai Jing Wu⁴ and Qianjin Lu⁵, ¹Department of Dermatology, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Department of Dermatology, Second Xiangya Hospital, Central South University, shangcha, China, ³Department of Dermatology, Second Xiangya Hospital, Central South University, changsha, China, ⁴Department of Dermatology, Second Xiangya Hospital, Central South University, sahngsha, China, ⁵Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose : Systemic lupus erythematosus (SLE) is a female predominant autoimmune disease characterized by overproduction of autoantibodies. The pathogenesis of SLE is complex. Several studies…
Abstract Number: 2689 • 2014 ACR/ARHP Annual Meeting
The CUL4^CRBN E3 Ubiquitin Ligase Modulator CC-220 Induces Degradation of the Transcription Factors Ikaros and Aiolos: Immunomodulation in Healthy Volunteers and Relevance to Systemic Lupus Erythematosus
Peter H. Schafer¹, Ying Ye², Lei Wu³, Jolanta Kosek⁴, Zhihong Yang⁵, Liangang Liu⁵, Michael Thomas⁵, Maria Palmisano⁵ and Rajesh Chopra⁵, ¹Celgene Corporation, Celgene Corporation, Summit, NJ, ²86 Morris Avenue, Celgene Corporation, Summit, NJ, ³Department of Translational Development, Celgene Corporation, Summit, NJ, ⁴Translational Development, Celgene Corporation, Summit, NJ, ⁵Celgene Corporation, Summit, NJ
Background/Purpose: CC-220 is an immunomodulatory compound that binds to cereblon (CRBN), part of the CUL4CRBN E3 ubiquitin ligase complex, which has been shown to ubiquitinate…
Abstract Number: 2667 • 2014 ACR/ARHP Annual Meeting
First-Trimester Disease Activity Does Not Predict Pre-Eclampsia in SLE Pregnancy
Khaled Alderaan¹, Laurence S. Magder² and Michelle Petri³, ¹King Fahad Specilaist Hospital, Dammam, Saudi Arabia, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Preeclampsia complicates up to 35% of lupus pregnancies compared to 8% of general population pregnancies. SLE has up to a 3-fold increased rate of…
Abstract Number: 2635 • 2014 ACR/ARHP Annual Meeting
Noncalcified Plaque Progression in Systemic Lupus Erythematosus
Adnan Kiani¹, Armin Zadeh², Joao Lima², Laurence S. Magder³ and Michelle Petri⁴, ¹1830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Coronary atherosclerosis is a major cause of morbidity and mortality in SLE. New technology, computed tomoangiography (CTA) can measure non-calcified coronary plaque (NCP),…
Abstract Number: 2648 • 2014 ACR/ARHP Annual Meeting
Prednisone Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus
Xiangyang Huang¹, Laurence S. Magder² and Michelle Petri³, ¹Sichuan University School of Medicine, Sichuan, China, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Depression affects as many as 30% of SLE patients. Most studies of risk factors for depression among SLE patients have been cross-sectional, and thus…
Abstract Number: 2647 • 2014 ACR/ARHP Annual Meeting
Predictors of Incident Seizure in Systemic Lupus Erythematosus
Xiangyang Huang¹, Laurence S. Magder² and Michelle Petri³, ¹Sichuan University School of Medicine, Sichuan, China, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: We identified the rate and risk factors for first occurrences of seizure based on a large closely followed longitudinal cohort of patients with systemic…
Abstract Number: 2622 • 2014 ACR/ARHP Annual Meeting
Systemic LUPUS Erythematosus in Spanish Males
Anne Riveros-Frutos¹, Irma Casas², Iñigo Rúa-Figueroa³, José Maria Pego-Reigosa⁴, M. Jesús García de Yebenes⁵, Alejandro Olivé⁶, Jose Rosas⁷, Paloma Vela⁸, Monica Ibanez Barcelo⁹, Vicente Torrente¹⁰, Ivan Castellvi¹¹, Javier Narváez¹², Mireia Moreno¹³, R. Blanco Alonso¹⁴, Víctor Martínez Taboada¹⁵, Jaime Calvo-Alen¹⁶, Mª Angeles Aguirre¹⁷, Mercedes Freire¹⁸, Enrique Raya¹⁹, Celia Erausquin²⁰, Esther Uriarte²¹, Elvira Díez Álvarez²², Tomás Vázquez Rodríguez²³, Antonio Fernández Nebro²⁴, Eva Tomero²⁵, Paloma García de la Peña²⁶, Ana Sánchez Atrio²⁷, Monica Fernández de Castro²⁸, Antonio Zea²⁹, Patricia Richi³⁰, Francisco Lopez Longo³¹, María Galindo-Izquierdo³², Patricia Carreira³³, Gema Bonilla³⁴, Carlos Marras Fernández Cid³⁵, Maria Loreto Horcada³⁶, Carlos Montilla³⁷, Blanca Hernández-Cruz³⁸, José Marenco de la Fuente³⁹, Marian Gantes⁴⁰, Olaia Fernández Berrizbeitia⁴¹, Juan J. Alegre⁴², Ángela Pecondón Español⁴³, Manuel Rodríguez-Gómez⁴⁴, Victor Quevedo⁴⁵, José Hernández Beiraín⁴⁶ and Lucía Silva Fernández⁴⁷, ¹Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ²Preventive Medicine, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ³Rheumatology, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁴Rheumatology, Hospital Meixoeiro, Vigo, Spain, ⁵Rheumatology, Research Unit of the SER, Madrid, Spain, ⁶Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁷Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ⁸Rheumatology, Hospital General de Alicante. Spain, Alicante, Spain, ⁹H. Son Llatzer, Palma de Mallorca, Spain, ¹⁰Rheumatology, Hospital Moisès Broggi, Barcelona, Spain, ¹¹Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ¹³Rheumatology, Hospital Parc Taulí, Sabadell, Spain, ¹⁴Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹⁵Rheumatology, Marqués de Valdecilla, Santander, Spain, ¹⁶Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ¹⁷Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ¹⁸Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁹Rheumatology, University Hospital San Cecilio, Granada, Spain, ²⁰Rheumatology, Hospital Dr, Negrín, Las Palmas Gran Canarias, Spain, ²¹Rheumatology, Hospital de Donosti, San Sebastian, Spain, ²²Rheumatology, Hospital de León. Spain, León, Spain, ²³Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ²⁴Rheumatology, Hospital Carlos Haya. Malaga, Malaga, Spain, ²⁵Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁶Rheumatology, Hospital Norte Sanchinarro, Madrid, Spain, ²⁷Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, ²⁸Hospital Puerta del Hierro, Madrid, Spain, ²⁹Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ³⁰Hospital Infanta Sofía, Madrid, Spain, ³¹Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ³²Rheumatology, Hospital 12 de octubre, Madrid, Spain, ³³Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³⁴Rheumatology, Hospital La Paz, Madrid, Spain, ³⁵Hospital Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ³⁷Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ³⁸Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ³⁹Rheumatology, Hospital de Valme, Sevilla, Spain, ⁴⁰Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ⁴¹Rheumatology, Hospital de Basurto, Bilbao, Spain, ⁴²Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ⁴³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴⁴Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴⁵Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ⁴⁷Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain

Background/Purpose: To describe the demographic, clinical and immunological manifestations in male patients with Systemic Lupus Erythematosus(SLE) Methods: Patients diagnosed of SLE that were in the…
Abstract Number: 1859 • 2014 ACR/ARHP Annual Meeting
Age-Specific Predictors of Mortality in SLE
Dominique Ibanez¹, Dafna D. Gladman² and Murray B. Urowitz², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mortality is 3 to 5 times greater in SLE patients then it is in the general population – especially among younger patients where it…
Abstract Number: 1652 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Lupus Nephritis and Ethnic Disparities in Systemic Lupus Erythematosus
Adnan Kiani¹, Laurence S. Magder² and Michelle Petri³, ¹1830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis eventually occurs in 50% of Caucasian SLE patients and 75% of African-Americans. African Americans have a more severe presentation of SLE and…
Abstract Number: 1320 • 2014 ACR/ARHP Annual Meeting
Analysis of Risk Factors for Thrombosis in Pediatric Patients with Systemic Lupus Erythematosus
Kyla D. Driest¹, Mollie S. Sturm², Sarah H. O'Brien³, Charles H. Spencer⁴ and Stacy P. Ardoin⁵, ¹Rheumatology, OSU Pediatrics, Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Hematology, Nationwide Children's Hospital, Columbus, OH, ⁴Rheumatology, Nationwide Childrens Hospital, Columbus, OH, ⁵Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher thrombotic risk compared to the general population, and arterial and venous thromboses impart substantial morbidity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].